Giá trị dự đoán của dấu 70 gen đối với hóa trị bổ trợ trong ung thư vú giai đoạn đầu

Trialists’ Collaborative Group (EBCTCG) et al (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717 National Comprehensive Cancer Network. Practice Guidelines in Oncology—v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. 12-11-2009 Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329 Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G (2007) International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9(6):R81 van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536 van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009 Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826 Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8(3):R25 Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272 Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607–616 Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V et al (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14(9):2601–2608 Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734 Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183–1192 Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C et al (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117(3):483–495 Knauer M, Wenzl E, Rutgers EJT, Linn SC, van’t Veer LJ (2009) Gene expression profiling in breast cancer—design of a pooled database to address open questions. Eur Surg 41(5):221–227 Bueno-de-Mesquita JM, van Harten WH, Retel VP, van’t Veer LJ, van Dam FS, Karsenberg K et al (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8(12):1079–1087 Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A et al (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116(2):295–302 Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ et al (2009) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. doi:10.1093/annonc/mdp388 Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N et al (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7:278 Ioannidis JP (2006) Gene expression profiling for individualized breast cancer chemotherapy: success or not? Nat Clin Pract Oncol 3(10):538–539 Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG (2005) Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2(3):209–217 Cardoso F, van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26(5):729–735 Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7(4):347–350 Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65 Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800 Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284–2293 Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8(12):1071–1078 Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA et al (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24(26):4236–4244 Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V et al (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27(19):3185–3191 Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362(9381):362–369 Dressman HK, Hans C, Bild A, Olson JA, Rosen E, Marcom PK et al (2006) Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 12(3 Pt 1):819–826 Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM et al (2005) Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11(20):7434–7443 Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23(29):7265–7277 Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y et al (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23(3):422–431 Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T et al (2006) Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 99(1):9–17 Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R et al (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12(11):1294–1300 Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H et al (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24(12):1839–1845 Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ et al (2010) The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 119(3):551–558